EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing ...

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with ...

Fintel reports that on July 14, 2025, Wedbush initiated coverage of Crescent Biopharma (NasdaqCM:CBIO) with a Outperform recommendation. Analyst Price Forecast Suggests 28.50% Upside As of March 27, ...

Fintel reports that on June 18, 2025, LifeSci Capital initiated coverage of GlycoMimetics (NasdaqCM:CBIO) with a Outperform recommendation. Analyst Price Forecast Suggests 25.25% Upside As of March 27 ...

--- The United States FDA Clears Initiation of a Phase II Efficacy Trial in Immunoglobulin A Nephropathy (IgAN) Patients: a renal disorder CLEVELAND, Dec. 02, 2024 (GLOBE NEWSWIRE) -- NovelMed is ...

The report also covers products from therapy areas such as Immunology, Hematological Disorders, Cardiovascular, and Central Nervous System which include the indications Autoimmune Disorders, ...

C1q is the target recognition protein of the classical complement pathway and a major connecting link between innate and acquired immunity. As a charge pattern recognition molecule of innate immunity, ...